| MeSH term | MeSH ID | Detail |
|---|---|---|
| Inflammation | D007249 | 119 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Tibial Fractures | D013978 | 4 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Endometriosis | D004715 | 29 associated lipids |
| Liver Cirrhosis | D008103 | 67 associated lipids |
| Cerebral Hemorrhage | D002543 | 13 associated lipids |
2,3-dinor, 6-keto-PGF1alpha
2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha
NCBI Entrez Crosslinks
All references with 2,3-dinor, 6-keto-PGF1alpha
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ritter JM et al. | Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. | 1989 | Br J Clin Pharmacol | pmid:2590611 |
| Regan CL et al. | Reduced fetal exposure to aspirin using a novel controlled-release preparation in normotensive and hypertensive pregnancies. | 1998 | Br J Obstet Gynaecol | pmid:9692413 |
| Reilly IA et al. | Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. | 1986 | Br Med J (Clin Res Ed) | pmid:3083991 |
| Aitokallio-Tallberg A et al. | Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment. | 1989 | Br. J. Cancer | pmid:2803956 |
| Kaaja R et al. | Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins. | 2001 | Br. J. Haematol. | pmid:11552994 |
| Rousson D et al. | Increased in vivo biosynthesis of prostacyclin and thromboxane A2 in chronic idiopathic thrombocytopenic purpura. | 1989 | Br. J. Haematol. | pmid:2669929 |
| Ward PS et al. | Excretion of metabolites of prostacyclin and thromboxane by rats with nephrotoxic nephritis: effects of interleukin-1. | 1991 | Br. J. Pharmacol. | pmid:1933130 |
| Henrion D et al. | Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. | 1997 | Br. J. Pharmacol. | pmid:9146891 |
| Zhao L et al. | Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. | 2009 | Br. J. Pharmacol. | pmid:19220291 |
| Aitokallio-Tallberg AM et al. | Urinary excretion of degradation products of prostacyclin and thromboxane is increased in patients with gestational choriocarcinoma. | 1991 | Cancer Res. | pmid:1868436 |